Version 1
: Received: 6 May 2024 / Approved: 8 May 2024 / Online: 8 May 2024 (10:35:00 CEST)
How to cite:
Maris, D.; Dastiridou, A.; Kotoula, M.; Karathanou, A.; Tsironi, E. E.; Bargiota, A.; Androudi, S. Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab. Preprints2024, 2024050460. https://doi.org/10.20944/preprints202405.0460.v1
Maris, D.; Dastiridou, A.; Kotoula, M.; Karathanou, A.; Tsironi, E. E.; Bargiota, A.; Androudi, S. Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab. Preprints 2024, 2024050460. https://doi.org/10.20944/preprints202405.0460.v1
Maris, D.; Dastiridou, A.; Kotoula, M.; Karathanou, A.; Tsironi, E. E.; Bargiota, A.; Androudi, S. Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab. Preprints2024, 2024050460. https://doi.org/10.20944/preprints202405.0460.v1
APA Style
Maris, D., Dastiridou, A., Kotoula, M., Karathanou, A., Tsironi, E. E., Bargiota, A., & Androudi, S. (2024). Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab. Preprints. https://doi.org/10.20944/preprints202405.0460.v1
Chicago/Turabian Style
Maris, D., Alexandra Bargiota and Sofia Androudi. 2024 "Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab" Preprints. https://doi.org/10.20944/preprints202405.0460.v1
Abstract
Τhis study aims to assess changes in the fovea avascular zone (FAZ) in treatment naïve patients receiving aflibercept or ranibizumab injections for diabetic macular edema (DME). This is a prospective study recruiting patients with treatment-naïve DME. Best corrected visual acuity (BCVA) testing, OCT and OCT-angiography (OCTA) imaging were performed at baseline and 1 month after each injection. Injections of either aflibercept or ranibizumab were administered monthly for 6 consecutive months. FAZ in the superficial (SCP) and the deep capillary plexus (DCP) using OCTA was recorded for each visit. Fifty eyes from 50 patients with a mean age of 67.010.7 years were included in the study Twenty-five patients received aflibercept and 25 received ranibizumab. BCVA was 40.810.0 and increased to 52.17.9 ETDRS letters at the last visit (p<0.001). CRT was 295.634.0 at baseline and 247.929.7 at the last study visit (p<0.001). SCP FAZ was 350.679.5μm2 at baseline and 339.071.3μm2 after 6 monthly injections (p=0.132). DCP FAZ was 558.6199.0μm2 at baseline and 459.5156.1μm2 after 6 monthly injections (p<0.001). There was no effect of the choice of ranibizumab or aflibercept on DCP FAZ change (p=0.277). In conclusion, treatment with 6 monthly injections of ranibizumab and aflibercept led to an increase in BCVA and a decrease in CRT and DCP FAZ area. Both drugs led to an improvement in DCP ischemia.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
